Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2018-2021

ABSTRACT

The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer. Detailed Description This study has two phases: "Discovery" cohort and "Validation" cohort. The "Discovery" phase of this study will obtain tissue samples in a retrospective manner. The investigators will perform genome-scale DNA Methylation analysis to obtain a panel of candidate methylated DNA biomarkers. Twenty archival primary serous epithelial ovarian cancer and twenty archival normal ovarian and salpingeal tissues will be identified by running a report of diagnosis. During the "Validation" phase of this study, blood and tissue samples will be obtained in a prospective manner. The patients will be undergoing consultation for undiagnosed pelvic mass and are being scheduled for a diagnostic laparoscopic biopsy. At the time of their consultation, patients will be recruited and consented for this phase of the study. More... »

URL

https://clinicaltrials.gov/show/NCT03622385

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.\n\nDetailed Description\nThis study has two phases: \"Discovery\" cohort and \"Validation\" cohort. The \"Discovery\" phase of this study will obtain tissue samples in a retrospective manner. The investigators will perform genome-scale DNA Methylation analysis to obtain a panel of candidate methylated DNA biomarkers. Twenty archival primary serous epithelial ovarian cancer and twenty archival normal ovarian and salpingeal tissues will be identified by running a report of diagnosis. During the \"Validation\" phase of this study, blood and tissue samples will be obtained in a prospective manner. The patients will be undergoing consultation for undiagnosed pelvic mass and are being scheduled for a diagnostic laparoscopic biopsy. At the time of their consultation, patients will be recruited and consented for this phase of the study.", 
    "endDate": "2021-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03622385", 
    "keywords": [
      "exploration", 
      "DNA methylation", 
      "early detection", 
      "epithelial ovarian cancer", 
      "marker", 
      "plasma", 
      "diagnostics", 
      "diagnosis", 
      "discovery cohort", 
      "validation cohort", 
      "discovery phase", 
      "tissue sample", 
      "genome scale", 
      "panel", 
      "methylated DNA", 
      "tissue", 
      "validation phase", 
      "blood", 
      "prospective manner", 
      "patient", 
      "Referral and Consultation", 
      "mass"
    ], 
    "name": "Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03622385"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00028.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.486749.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411588.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2018-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.ygyno.2010.09.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002289452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01224-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004608164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fmolb.2015.00013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011708684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2353/jmoldx.2009.080072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013995639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024942368", 
          "https://doi.org/10.1038/nature11412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ajog.2005.05.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025135148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100164642"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2017.21894", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101016243"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03622385"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03622385'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03622385'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03622385'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03622385'


 

This table displays all metadata directly associated to this object as RDF triples.

68 TRIPLES      16 PREDICATES      46 URIs      31 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03622385 schema:about anzsrc-for:3142
2 schema:description The purpose of this study is to determine if there are markers in plasma that can be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer. Detailed Description This study has two phases: "Discovery" cohort and "Validation" cohort. The "Discovery" phase of this study will obtain tissue samples in a retrospective manner. The investigators will perform genome-scale DNA Methylation analysis to obtain a panel of candidate methylated DNA biomarkers. Twenty archival primary serous epithelial ovarian cancer and twenty archival normal ovarian and salpingeal tissues will be identified by running a report of diagnosis. During the "Validation" phase of this study, blood and tissue samples will be obtained in a prospective manner. The patients will be undergoing consultation for undiagnosed pelvic mass and are being scheduled for a diagnostic laparoscopic biopsy. At the time of their consultation, patients will be recruited and consented for this phase of the study.
3 schema:endDate 2021-10-01T00:00:00Z
4 schema:keywords DNA methylation
5 Referral and Consultation
6 blood
7 diagnosis
8 diagnostics
9 discovery cohort
10 discovery phase
11 early detection
12 epithelial ovarian cancer
13 exploration
14 genome scale
15 marker
16 mass
17 methylated DNA
18 panel
19 patient
20 plasma
21 prospective manner
22 tissue
23 tissue sample
24 validation cohort
25 validation phase
26 schema:name Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
27 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03622385
28 schema:sdDatePublished 2019-03-07T15:28
29 schema:sdLicense https://scigraph.springernature.com/explorer/license/
30 schema:sdPublisher Na05390b9972c46c0a737b1ab52c991c3
31 schema:sponsor https://www.grid.ac/institutes/grid.411588.1
32 https://www.grid.ac/institutes/grid.486749.0
33 schema:startDate 2018-10-01T00:00:00Z
34 schema:subjectOf sg:pub.10.1038/nature11412
35 https://doi.org/10.1001/jama.2017.21894
36 https://doi.org/10.1016/j.ajog.2005.05.005
37 https://doi.org/10.1016/j.ygyno.2010.09.019
38 https://doi.org/10.1016/s0140-6736(15)01224-6
39 https://doi.org/10.2353/jmoldx.2009.080072
40 https://doi.org/10.3322/caac.21442
41 https://doi.org/10.3389/fmolb.2015.00013
42 schema:url https://clinicaltrials.gov/show/NCT03622385
43 sgo:license sg:explorer/license/
44 sgo:sdDataset clinical_trials
45 rdf:type schema:MedicalStudy
46 Na05390b9972c46c0a737b1ab52c991c3 schema:name Springer Nature - SN SciGraph project
47 rdf:type schema:Organization
48 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
49 rdf:type schema:DefinedTerm
50 sg:pub.10.1038/nature11412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024942368
51 https://doi.org/10.1038/nature11412
52 rdf:type schema:CreativeWork
53 https://doi.org/10.1001/jama.2017.21894 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101016243
54 rdf:type schema:CreativeWork
55 https://doi.org/10.1016/j.ajog.2005.05.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025135148
56 rdf:type schema:CreativeWork
57 https://doi.org/10.1016/j.ygyno.2010.09.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002289452
58 rdf:type schema:CreativeWork
59 https://doi.org/10.1016/s0140-6736(15)01224-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004608164
60 rdf:type schema:CreativeWork
61 https://doi.org/10.2353/jmoldx.2009.080072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013995639
62 rdf:type schema:CreativeWork
63 https://doi.org/10.3322/caac.21442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100164642
64 rdf:type schema:CreativeWork
65 https://doi.org/10.3389/fmolb.2015.00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011708684
66 rdf:type schema:CreativeWork
67 https://www.grid.ac/institutes/grid.411588.1 schema:Organization
68 https://www.grid.ac/institutes/grid.486749.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...